Dmitry Balyasny’s AstraZeneca AZN Stock Holding History

Dmitry Balyasny’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-137,550	Closed	-$25.3M	–	2889
2025 Q4	$25.3M	Buy	137,550 +91,900	+201%	+$16.1M	0.03%	605
2025 Q3	$7M	Buy	+45,650	New	+$6.91M	0.01%	1220
2024 Q4	–	Sell	-4,750	Closed	-$740K	–	2727
2024 Q3	$740K	Buy	+4,750	New	+$767K	﹤0.01%	2083
2021 Q1	–	Sell	-68,750	Closed	-$6.87M	–	1749
2020 Q4	$6.87M	Buy	+68,750	New	+$7.28M	0.04%	553
2019 Q2	–	Sell	-450,000	Closed	-$36.4M	–	1466
2019 Q1	$36.4M	Buy	+450,000	New	+$35.5M	0.24%	110
2018 Q2	–	Sell	-21,500	Closed	-$1.5M	–	1775
2018 Q1	$1.5M	Buy	+21,500	New	+$1.49M	0.01%	1080
2017 Q3	–	Sell	-100,000	Closed	-$6.82M	–	1872
2017 Q2	$6.82M	Buy	+100,000	New	+$6.53M	0.03%	656

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dmitry Balyasny's AZN Position: Q2 2026 in Review

Dmitry Balyasny sold out of AstraZeneca (AZN) in Q2 2026, closing a stake of 148,684 shares — an estimated $29.3M sold.

Dmitry Balyasny first reported a position in AZN in Q3 2013 and held it in 31 quarters. The position peaked at $99.1M in Q4 2025. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Dmitry Balyasny reported no remaining AstraZeneca position as of Q2 2026 after selling out during the quarter.
Dmitry Balyasny sold 148,684 AstraZeneca shares in Q2 2026, an estimated $29.3M.
Dmitry Balyasny first reported a position in AstraZeneca in Q3 2013 and held it in 31 quarters.
Dmitry Balyasny's AstraZeneca position peaked at $99.1M in Q4 2025.
1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.